Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07937449
PHASE3

The Efficacy and Safety of DLBS3233 in Adults With Prediabetes

Sponsor: Dexa Medica Group

View on ClinicalTrials.gov

Summary

This is a 3-arm, prospective, randomized, double-blind, parallel, controlled, non-inferiority study comparing DLBS3233 at a dose of 100 mg once daily; DLBS3233 at a dose of 200 mg once daily; and Metformin XR 500 mg twice daily for a 12-week course of therapy. DLBS3233 is a bioactive fraction derived from a combination of Lagerstroemia speciosa and Cinnamomum burmanii. DLBS3233 exhibits antidiabetic properties by enhancing insulin signaling, improving glucose uptake, modulating lipid metabolism, and reducing insulin resistance.

Official title: A Randomized, Double-Blind, Parallel, Controlled, Non-Inferiority Study to Evaluate the Efficacy and Safety of DLBS3233 in Adults With Prediabetes

Key Details

Gender

FEMALE

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2025-07-07

Completion Date

2026-10-15

Last Updated

2026-11-16

Healthy Volunteers

No

Conditions

Interventions

DRUG

DLBS3233

DLBS3233 will be given into two different groups; 1 capsule of DLBS3233 100 mg once daily and 2 capsules of DLBS3233 100 mg once daily.

DRUG

Metformin XR

Metformin XR 500 mg will be given 1 tablet twice daily as a comparator.

Locations (2)

Department of Internal Medicine, Dr. Soetomo Regional Public Hospital

Surabaya, East Java, Indonesia

Equilab International

Jakarta, Jakarta Special Capital Region, Indonesia